People · Operator
Named in public records as an officer, director or promoter · active 2017–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Seraph Biosciences, Inc. | — | Biotechnology | Series A | $10.0M | $253.9M | 2017 |
Charles Shanley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Shanley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Shields | 1 | 3 |
| Scott Merz | 1 | 3 |
| Matthew Cullen | 1 | 3 |
| James Mault | 1 | 2 |
| James Nadeem Shanley | 1 | 1 |
| Richard Nadeem Creager | 1 | 1 |
| Braden Nadeem Robison | 1 | 1 |
| Paul Glantz | 1 | 1 |
| Gregory Auner | 1 | 1 |
| James Shanley | 1 | 1 |
| Braden Robison | 1 | 1 |
| MARK TREXLER | 1 | 1 |
| Gary Loveman | 1 | 1 |
| Ahmad Nadeem Ishaque | 1 | 1 |
| Scott Nadeem Merz | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.